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Prescription Stimulants’ Effects on Healthy Inhibitory
Control, Working Memory, and Episodic Memory:
A Meta-analysis
Irena P. Ilieva, Cayce J. Hook, and Martha J. Farah
Abstract
■ The use of prescription stimulants to enhance healthy cogni-
tion has significant social, ethical, and public health implications.
The large number of enhancement users across various ages
and occupations emphasizes the importance of examining these
drugs’ efficacy in a nonclinical sample. The present meta-analysis
was conducted to estimate the magnitude of the effects of
methylphenidate and amphetamine on cognitive functions cen-
tral to academic and occupational functioning, including inhibi-
tory control, working memory, short-term episodic memory,
and delayed episodic memory. In addition, we examined the
evidence for publication bias. Forty-eight studies (total of 1,409
participants) were included in the analyses. We found evidence
for small but significant stimulant enhancement effects on in-
hibitory control and short-term episodic memory. Small effects
on working memory reached significance, based on one of our
two analytical approaches. Effects on delayed episodic memory
were medium in size. However, because the effects on long-term
and working memory were qualified by evidence for publication
bias, we conclude that the effect of amphetamine and methyl-
phenidate on the examined facets of healthy cognition is proba-
bly modest overall. In some situations, a small advantage may
be valuable, although it is also possible that healthy users resort
to stimulants to enhance their energy and motivation more than
their cognition. ■
INTRODUCTION
The scientific and popular literatures both document
the use of prescription medications by healthy young peo-
ple to enhance cognitive performance in school and on
the job (e.g., Smith & Farah, 2011; Talbot, 2009). This
practice, called “cognitive enhancement,” has provoked
wide discussion of its potential social, ethical, and public
health consequences (Greely, 2013; Sahakian & Morein-
Zamir, 2011; Farah et al., 2004). Recently, another ques-
tion concerning cognitive enhancement has arisen: To
what degree do the medications used for cognitive en-
hancement in fact improve the abilities of cognitively
normal individuals?
In view of the prevalence of cognitive enhancement
and the intensity of academic and policy interest in this
practice, it is surprising that the answer to this question
has not been clearly established. The empirical literature
on the effects of these stimulants on cognition in normal
participants has yielded variable results, with some
reviewers doubting their efficacy altogether. For example,
in reviewing the literature on the cognitive effects of
methylphenidate, Repantis, Schlattmann, Laisney, and
Heuser (2010) concluded that they were “not able to
provide sufficient evidence of positive effects in healthy
individuals from objective tests.” Hall and Lucke (2010)
stated: “There is very weak evidence that putatively neuro-
enhancing pharmaceuticals in fact enhance cognitive
function.” Advokat (2010) concluded her review of the
literature by stating that “studies in non-ADHD adults sug-
gest that stimulants may actually impair performance on
tasks that require adaptation, flexibility and planning.”
Smith and Farah (2011) attempted to test the hypothe-
sis that stimulants enhance cognitive performance in nor-
mal healthy participants with a systematic literature
review. We included studies of amphetamine and methyl-
phenidate’s effects on episodic and procedural memory
and three categories of executive function: working mem-
ory, inhibitory control, and third category of other execu-
tive function tasks that did not fit into either of the first
two. Results were mixed, with large effects, small effects,
and null effects all reported. For example, over a third of
the executive function studies reported null results. One
interpretation of this pattern is that the drugs confer
a small benefit, which may fail to be detected in some
studies because of inadequate power. The other possibility
is that chance positive findings, combined with publication
bias, may be responsible for the positive evidence that
exists in the literature. Thus, despite the large literature
included in our review, we were forced to conclude that
“there remains great uncertainty regarding the size and
robustness of these effects.”Meta-analysis is a method thatUniversity of Pennsylvania
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can distinguish between the competing interpretations
of the findings in the cognitive enhancement literature.
The primary goal of the present meta-analysis is to
obtain a quantitative estimate of the cognitive effects
of the stimulants amphetamine and methylphenidate.
They are commonly prescribed for the treatment of
attention deficit hyperactivity disorder (ADHD) but are
frequently diverted for enhancement use by students
and others (e.g., Wilens et al., 2008; Poulin, 2007; McCabe,
Teter, & Boyd, 2006). Guided by the findings of Smith
and Farah’s (2011) review, we focus on the cognitive pro-
cesses that seemed most likely to be enhanced by stim-
ulants, specifically inhibitory control, working memory,
and episodic memory. In addition, because this earlier
review found the strongest evidence of episodic memory
enhancement after long delays between learning and test,
we distinguish between episodic memory tested soon
after learning (within 30 min after learning trials) and
episodic memory tested after longer intervals (1 hr to
1 week).
The meta-analysis has two additional goals: one is to
test hypotheses about moderators of the effects, that is,
differences between studies that might account for the
variability in effectiveness noted across different studies.
For example, perhaps one of the stimulants is effective
and the other less so, or perhaps low doses are more ef-
fective than higher doses. The final goal is to assess the
role of publication bias in shaping the literature and poten-
tially inflating effect size estimates. This would happen if,
as hypothesized (e.g., Smith & Farah, 2011), under-
powered studies obtained large statistically significant
effects by chance and thereby entered the literature while
the balancing effects of smaller or null results from similar
studies remained unpublished.
METHODS
Search Strategies
Online databases PubMed and PsychInfo were searched
with key words amphetamine and methylphenidate,
each combined with each of the following: executive
function, executive control, cognitive control, inhibi-
tory control, inhibition, working memory, flanker,
stop signal task, stop task, no-go, card-sort, ID/ED, set
shifting, Sternberg memory, Stroop, Digit Span, memory,
learning, recall, recognition, and retention. These
searches were narrowed to exclude research on non-
human participants, qualitative studies, and nonempirical
publications (e.g., review articles, meta-analyses, lectures,
news articles, etc.). In addition, the reference sections
of the following review articles were searched for rele-
vant articles: Chamberlain et al. (2011), Smith and Farah
(2011), Advokat (2010), and Repantis et al. (2010). Finally,
we searched the list of articles being reviewed by an
American Academy of Neurology committee studying cog-
nitive enhancement on which the last author serves. All
research published through the end of December 2012
were eligible.
We also sought relevant unpublished data to include in
the meta-analyses. Twenty researchers active in the area
were contacted for unpublished data on amphetamine or
methylphenidate effects on episodic memory, working
memory, or inhibitory control in healthy nonelderly
adults. In addition, 14 requests were made for additional
data from studies published in the past 10 years but re-
porting insufficient data to calculate effect sizes. This led
to obtaining two data sets of studies in progress or in
submission as well as additional effect size data from four
published reports. An additional unpublished pilot data
set from our laboratory was also included.
Criteria for Study Eligibility
Publication Type and Language
Empirical investigations in any report format were eligible
for inclusion in the meta-analysis. These included journal
articles as well as dissertations, conference presentations,
and unpublished data sets. The latter three were con-
sidered in an attempt to minimize the influence of publi-
cation bias on the obtained effect size estimates. Only
reports in English were included.
Participants
Eligible participants were young and middle-aged adults.
Research on children, elderly, criminal, or mentally ill
participants was excluded. Studies were also excluded if
the experimental procedure entailed sleep deprivation.
Research Design: Methodological Quality
A double-blind, placebo-controlled design was required for
inclusion. This criterion aimed to maximize the methodo-
logical quality of the meta-analyzed material.
Research Design: Intervention
Eligible interventions were orally administered amphet-
amine and methylphenidate, with drugs administered
before the start of the cognitive protocol (e.g., not after
learning in a memory experiment). We only included
research on single-dose administration (the only study
on the effect of repeated administration was excluded
because of lack of consistency of intervention strength
with the rest of the available research). In the included
studies, the interval between drug administration and
the cognitive task ranged between 30 min and 4.5 hr
for amphetamine studies and 40 min and 4.5 hr for re-
search on methylphenidate. These intervals are within
the medications’ window of effectiveness (Volkow et al.,
1998; Angrist, Corwin, Bartlik, & Cooper, 1987; Vree &
Van Rossum, 1970). In addition, it is not unreasonable to
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suspect that these waiting times have ecological validity,
with users working or studying similar intervals after drug
intake.
Studies including multiple intervention arms, such as
different drugs or TMS, were included only if the effects
of amphetamine and methylphenidate could be assessed
in isolation (e.g., without concurrent TMS) and compared
with placebo.
Cognitive Systems under Investigation
Four abilities central to academic and professional work
were included based on the findings of Smith and Farah’s
(2011) literature review. They were inhibitory control, the
ability to override dominant, habitual, or automatic re-
sponses for the sake of implementing more adaptive,
goal-directed behaviors; working memory, the capacity
to temporarily store and manipulate information in the
service of other ongoing cognitive functions; episodic
memory, the ability to encode, store, and retrieve task-
relevant information, assessed shortly after learning (i.e.,
within 30 min) and at longer delays (1 hr to 1 week).
Whenever task descriptions were not sufficient to identify
the cognitive function tested, the data were excluded.
Outcome Measures
Performance can be measured by RT, overall accuracy,
or specific types of error such as misses or false alarms.
Overall in the literature, research reports varied in the
types and number of outcome measures reported for
each task. To maintain the validity and consistency of
outcome measures in our analyses, we designed an
a priori outcome selection procedure, as shown in
Table 1. Our outcome selection strategy favored the most
widely used and construct valid measures but also in-
cluded second-best options, whenever our first choices
were not reported. In general, we favored error measures
over RT measures unless accuracy was near ceiling; in
which case, RT data, if available, were coded. On tests
of inhibitory control, instead of overall accuracy, more
specific accuracy measures (or the relationships thereof )
were used, such as a measure of false alarms on go/no-go
tasks or the contrast in performance on incongruent and
congruent trials of Flanker and Stroop. Whenever rele-
vant, our main outcome measure was tailored to the
specific design of the task. Particularly, two variants of
the stop signal task of inhibitory control have been used
in the examined literature: a version where the probabil-
ity of stopping is allowed to vary and is the main measure
of inhibition (e.g., Fillmore, Kelly, & Martin, 2005) and a
version where the probability of stopping is held con-
stant (e.g., De Wit, Enggasser, & Richards, 2002; Logan,
Schachar, & Tannock, 1997), in which case stop signal
RT is the main outcome. Eligible outcome measures for
each task are shown in Table 1.
Process of Determining Study Eligibility
The search process, summarized in Figure 1, led to the
identification of 1,799 titles, which were narrowed down
to 1,505 after 294 duplicate articles were removed. After
screening the titles of these articles, additional 1,304 re-
ports were excluded for not meeting the inclusion criteria.
The remaining 201 studies were assessed for eligibility by
applying the exclusion criteria to the abstract and, in case
of insufficient data, to the full text.
Of the remaining 201 studies, 73 were excluded be-
cause the measured cognitive constructs (e.g., simple
RT, sustained attention, creativity, intelligence, fear con-
ditioning, motor performance, reward processing, proba-
bilistic learning, etc.) were outside the scope of the
present review. Twelve studies failed to meet the criteria
for eligible participants (mice: n = 1; elderly participants:
n = 6; children: n = 2; mentally ill participants: n = 2,
including one study on ADHD and one study on cocaine
abuse; criminal participants: n = 1). Eighteen reports
lacked a double-blind placebo-controlled design (when
these design features were not explicitly mentioned,
the study was excluded). Sixteen reports were excluded
because of ineligible intervention. These included four
studies that tested drugs other than amphetamine or
methylphenidate, four studies in which drugs were ad-
ministered intravenously, four studies conducted in the
context of sleep deprivation, two studies in which out-
comes were measured under TMS, one study in which
drug administration followed (as opposed to preceding)
learning, and one study that tested the effect of multiple
drug doses. Seven studies in language other than English
were excluded. Four studies could not be retrieved from
available online and article sources. Four studies were
excluded because of duplicating the data of already in-
cluded research. In 19 of the remaining otherwise eligible
studies, reported data were insufficient to calculate effect
size. The final analyses were based on 48 articles report-
ing at least one relevant effect size (44 published reports,
3 unpublished data sets, and 1 dissertation with 1,409
participants). The first and second authors independently
conducted the eligibility determination procedures; dis-
agreements were resolved by consensus after reviewing
the experimental reports.
Coding Procedures
All studies were coded by the first author, according to a
standardized coding manual. Coded variables included
means and standard deviations for performance under
drug and placebo, sample size, outcome measure, effect
direction, significance level, and several moderators. The
moderators and rationale for examining their effects were
that following:
(1) Drug (methylphenidate vs. amphetamine): This moder-
ator analysis was conducted to examine if amphet-
amine and methylphenidate differ in their cognitive
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Table 1. Eligible Measures for Examined Tasks
Cognitive Construct Task Eligible Measure(s)
Reference Supporting Choice
of Measure
Inhibitory control Stop Signal task Depending on task design:
•Stop signal RT (mean go RT
minus mean stop delay)
•Logan et al. (1997)
•Probability of inhibiting a response •Lappin and Eriksen (1966)
Go/no-go •False alarms or no-go accuracy •Aron, Robbins, and Poldrack
(2004); Helmers, Young,
and Pihl (1995)
Wisconsin Card Sort •Perseverative errors •Heaton, Chelune, Talley,
Kay, and Curtis (1993)
•If unavailable: accuracy
ID/ED • Perseverative extradimensional
shift errors
•Rogers et al. (1999)
Flanker •Difference or ratio between accuracy
in the congruent and incongruent
conditions
•Eriksen and Eriksen (1974)
•If unavailable: incongruent condition
accuracy
•If accuracy was at ceiling, corresponding
RTs were coded
Stroop •Difference or ratio between accuracy
in the congruent and incongruent
conditions
•Stroop (1935)
•If unavailable: incongruent condition
accuracy
•If accuracy was at ceiling, corresponding
RTs were coded
Antisaccade task •Error saccades toward the target •Everling and Fischer (1998)
Working memory n-backa •d0, difference between hits and false
alarms, or overall accuracy
•Jaeggi, Buschkuehl, Perrig,
and Meier (2010); Kane,
Conway, Miura, and
Colflesh (2007)
•If unavailable: omissions or hit rate
•When the accuracy measures from
the list above were at ceiling,
RTs were coded insteadb
Rapid Information
Processing
•Processing rate (digits presented
per minute)
•Fillmore et al. (2005)
Sternberg •Load effect •Sternberg (1966)
•If unavailable: accuracy
•If accuracy was at ceiling, corresponding
RTs were codedb
Digit Span •Accuracy •The Psychological Corporation
(2002)
•If unavailable: longest length of correctly
reported item
CANTAB Spatial Working
Memory
•Within and between search errors •Owen, Downes, Sahakian,
Polkey, and Robbins (1990)
•If unavailable: within- or between-search
errors
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enhancement potential. To our knowledge of the en-
hancement literature, no previous study has compared
the enhancement effects of these two medications.
(2) Dose (low vs. high): The cognitive effects of stimulants
are dose dependent (e.g., Cooper, et al. 2005). In
examining the role of dose in enhancement effects,
we defined a “high” dose as amphetamine ≥ 20 mg
and methylphenidate ≥ 40 mg. Doses below these
benchmarks were coded as “low.”
(3) Caffeine restriction (present vs. absent): We explored
the possibility that stimulants may be especially helpful
in countering caffeinewithdrawal, while possibly having
limited effects on non-caffeine-withdrawn individuals.
The presence or absence of instructions to abstain
from caffeinated beverages on the day of the experi-
ment was coded as a possible moderator.
(4) Gender distribution in the sample (percent male partici-
pants): In the past, higher rates of enhancement use
have been reported among male students (e.g., Tèter,
Mccabe, Cranford, Boyd, & Guthrie, 2005), and differ-
ences in stimulants’ subjective effects have been shown
to vary as a function of gender and menstrual phase
(White, Justice, & DeWit, 2002). The percentage of men
in the study sample was therefore tested as amoderator.
(5) Risk of ceiling or floor effects (suspected vs. not):
Ceiling and floor effects could attenuate the estimated
Table 1. (continued )
Cognitive Construct Task Eligible Measure(s)
Reference Supporting Choice
of Measure
Spatial Delayed Response •Accuracy •Postle, Jonides, Smith, Corkin,
and Growdon (1997)
Other WM measures •d0 or accuracy •Jaeggi et al. (2010), Kane et al.
(2007)
•For spatial tasks: error to position and
positional fit
•If unavailable: omission errors
Immediate and delayed
episodic memory
Recall (free and cued)
and recognition tests
•Sensitivity (d0 or a0), proportion of
hits minus proportion of false
alarms, accuracy, or number of
trials to criterion
•Henson, Rugg, Shallice, and
Dolan (2000)
•If unavailable: hit rate
aOnly data from 2- and 3-back tasks were coded, excluding data from 0-back conditions (which capitalize on sustained attention more than working
memory) and 1-back conditions (which, while taxing some working memory components, such as online maintenance, minimally tax other facets of
working memory, such as monitoring and manipulation). Thus, we only included the n-back conditions that maximized the possibility of detecting
drug effect and minimized the possibility of ceiling effects.
bWhen the data did not allow an inference about the presence or absence of ceiling or floor effects (i.e., the floor or the ceiling of the scale was not
clearly defined or apparent), both accuracy and RT measures were coded.
Figure 1. Process of
determining study
eligibility.
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effect size. In these analyses, we examined whether the
effect size in studies with no restriction of range dif-
fered from the effect size estimate in studies with sus-
pected floor or ceiling effects. A study was coded as
being at risk of range restriction if the larger among
the means in the drug and placebo conditions was less
than 1 SD away from the scale’s floor or if the smaller
mean was less than 1 SD away from the scale’s ceiling.
In case of moderation, our goal was to focus on the
effect size estimate in the group of studies without
suspected floor or ceiling effects.
(6) Reason to publish if drug effects are null (present vs.
absent): For the purpose of assessing publication
bias for reports of behavioral effects of stimulants,
we distinguished between effect sizes from studies
that focused only on the effects of amphetamine or
methylphenidate on healthy individuals and studies
that also included clinical groups, other drugs, or
nonbehavioral measures such as PET, fMRI, EEG, or
ERP. We expected that smaller stimulant enhance-
ment effects would be published in the context of
studies addressing multiple questions (because of
the higher likelihood of a positive finding given mul-
tiple measures and the greater resources invested in
testing clinical populations, measuring neural activity,
and administering multiple interventions).
(7) For working memory tasks: Stimulus type (verbal vs.
visual vs. spatial) and type of working memory sub-
process measured (maintenance vs. maintenance
plus manipulation). Different stimuli types and work-
ing memory subprocesses are supported by different
brain structures, raising a possibility for differential
susceptibility to stimulant effects (e.g., Martinussen,
Hayden, Hogg-Johnson, & Tannock, 2005; Wager &
Smith, 2003).
Effect sizes were calculated using means and standard
deviations. Where these descriptives were not presented,
we estimated them from published graphs. We favored
descriptive over inferential statistics based on previous
research showing that, in repeated-measures designs
(most of the included studies), effect size estimates from
descriptive statistics are less biased than those from
repeated-measures inferential statistics (Dunlap, Cortina,
Vaslow, & Burke, 1996). In the absence of descriptive data,
we estimated effect sizes from F (provided df = 1), t, and/
or p values. If effect sizes were directly reported,
we estimated their confidence intervals for requivalent
(Rosenthal & Rubin, 2003) and converted the values to
d. When data were unavailable from either reports or from
graphs, they were requested from authors.
The second author independently coded a random
sample of 44% of the means and standard deviations
(including data, estimated from graphs) in the placebo
and drug conditions. Analyses of reliability showed excel-
lent agreement (two-way mixed-model intraclass correla-
tion coefficient for absolute agreement > .99 in all cases).
Handling of Missing Data
Effect size data could not be retrieved or calculated from
19 reports. We performed all meta-analyses excluding all
missing data. We did not impute data in missing cells
because we had no reason to infer either zero or average
sizes of these unreported effects (Cooper, 2010). In other
words, we had no sufficient data to ensure that these
analyses would improve our effect size estimates, instead
of introducing error.
Statistical Methods
Effect Size Metrics
Hedge’s g was used as the primary effect size measure,
whereby a value of .2 is conventionally considered small,
.5 is considered medium, and .8 is considered large.
Hedge’s g is obtained by multiplying the effect size Cohen’s
d by a coefficient J, which corrects for the tendency for
studies with small sample sizes to bias the mean effect size
positively because of publication bias: J ¼ 1− 34df−1
 
. In
combining effect sizes, each was weighted by an estimate
of its precision, that is, the inverse of the squared standard
error of the effect size.
For within-subject designs, employed in most of the
meta-analyzed articles, we have the option of calculating
the effect size in two ways. Typically, for such designs, a
measure of performance change is scaled by units of vari-
ability of change. This addresses the question, “How much
drug-related benefit can one expect, relative to the variability
of change scores in the sample?” Alternatively, the effect size
can be expressed as the size of the drug treatment effect on
performance, measured in units of performance variability,
as in between-subject designs. Specifically, using this
approach, the difference in performance attributable
to the drug is measured against the standard deviation of
the sample’s placebo performance. In effect, this addresses
the question, “how far along the distribution of normal per-
formance does the drug push subjects?” This question is
very appropriate to the study of cognitive enhancement
when used to gain a competitive edge relative to an un-
medicated population. In addition, some authors have
argued that “subject differences are always of theoretical
interest” because “they are present in the population to
which we want to generalize,” justifying the calculation of
effect sizes from either within- or between-subject designs
in units of variability (Cortina & Nouri, 2000, p. 49). We
report both types of effect size analysis here, placing pri-
mary emphasis on effect sizes measured relative to normal
variability.
To conduct our primary analyses, we included re-
search with both within- and between-subject designs
and relied on effect sizes calculated as shown below.
These formulas, typically used for between-subject
designs, were modified so that the observed standard
deviations in the placebo condition are entered in the
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analyses as values for both medication and placebo con-
ditions. In particular:
g ¼ J MDRUG−MPBO
SDPOOLED
where SDPOOLED ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
NDRUG− 1ð ÞSD2PBO þ NPBO− 1ð ÞSD2PBOð Þ
NDRUG þNPBO− 2
r
and
SE ¼ SDPOOLED 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
NDRUG
þ 1NPBO
q
:
In these analyses, t, F, and p values were used to
derive effect sizes from between-subject designs, using
the following formulas: Hedge’s g ¼ J  t
ﬃﬃ
2
pﬃﬃﬃﬃﬃﬃﬃﬃ
2N1N2
N1þN2
p ; SE ¼ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
N1
þ 1N2 þ d
2
2 N1þN2ð Þ
q
(after converting p and F to t).
Inferential statistics from within-subject designs were
not included in these analyses because they inherently
reflect drug effects relative to variability of change, rather
than relative to performance variability.
Our secondary analyses focused on the change score
(drug minus placebo), specifically the average benefit
because of drug, relative to variability of change within
the sample. Only within-subject designs contained infor-
mation relevant to this question. To calculate Hedge’s g for
change in within-subject designs, the following formulas
were used.
g ¼ J  MDRUG−MPBOð Þ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2 1− Corrð Þp
SDDIFF
 !
where SDDIFF ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SD2DRUG þ SD2PBO− 2CorrSDDRUGSDPBO
p
and SE ¼ SDDIFFﬃﬃﬃ
N
p .
Alternatively, Hedge’s g ¼ J tﬃﬃﬃ
N
p and SE ¼ 1ﬃﬃﬃ
N
p 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1þ d22
q
.
These formulas require the value of the correlation be-
tween repeated measures, which were not reported in the
published studies. These values, necessary to adjust for
the dependency between repeated measures in effect size
calculations, were estimated based on similar data sets.1,2
Handling of Studies with More than One Effect Size
One of the assumptions of meta-analysis is that each ef-
fect size comes from an independent sample. If this as-
sumption is violated by the inclusion of more than one
effect size per study, between-study variance will be un-
derestimated, and the significance of the summary effect
size will be overestimated. The following steps were
taken to reduce the available data to a single effect size
per study.
(1) When effect sizes for more than one construct per
study were available, data on each construct (i.e.,
inhibition, working memory, and short- and long-term
episodic memory) were separated in an individual
meta-analysis.
(2) When multiple doses of a drug were compared with
placebo within the same study, effect size data from
all doses were coded and averaged.
(3) When, in a given study, effect sizes were reported
for more than one eligible task and/or measure per
construct, a single average effect size estimate per
construct was obtained.
(4) When outcome data were available from various time
intervals after the administration of the drug (e.g.,
when inhibitory control was tested 1, 2, and 3 hr after
drug administration or when long-term episodic mem-
ory was measured at various retention intervals), the
average effect size was entered in the main analyses.
Fixed vs. Random Effects Model
A fixed effects model assumes that the only source of
effect size variability is sampling error. It therefore pro-
duces an effect size estimate that describes the analyzed
studies but cannot be generalized to other trials. By con-
trast, in a random effects model, variability is assumed to
arise from both sampling error and between-study vari-
ability. Effect sizes derived from this model can be gen-
eralized to research outside of the analyzed studies. For
the present meta-analysis, we selected a random effects
model because of the variability between individual studies
in each meta-analysis (different drugs, doses, waiting times
between drug administration and testing, measures of each
specific cognitive function, individual differences between
samples) and also because we wanted to generalize the
findings beyond the examined research.
Estimation of Heterogeneity
Tests for heterogeneity determine whether the dispersion
of the individual effect sizes around their mean value is
greater than predicted solely on the basis of subject-level
sampling error. One of the tests employed uses the Q
statistic, which, if significant, rejects a null hypothesis of
homogeneity. The second test, based on the I2 statistic,
generates an estimate of the between-study variance as a
percentage of the total variance (between subjects plus
subject level). Conventions for low, moderate, and high
heterogeneity correspond to I2 values of 25, 50, and 75,
respectively (Lipsey & Wilson, 2001).
Moderator Analyses
Most commonly in the literature, moderator analyses are
conducted only after a finding of significant heterogeneity.
In contrast to this approach, we decided to conduct mod-
erator analyses regardless of the results of the heterogene-
ity tests because a homogeneous set of findings may
emerge either in the absence of moderators or in the pres-
ence of moderators whose effects cancel each other out.
We examined the effect of the dichotomous moder-
ators described earlier using mixed effects analyses. This
analytical model assumes that the effect size variation is
due to a combination of systematic associations between
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moderators and effect sizes, random differences between
studies, and subject-level sampling error. Finally, the mod-
erating role of gender composition (measured as percent
male) was examined through meta-regression, given the
continuous nature of this moderator.
A feature of the data on some moderator variables
demanded the following modification in some of the anal-
yses. When analyzing the moderating role of dose, ceiling/
floor effects, working memory stimulus type, and working
memory subprocess, there were several cases of more than
one level of the moderating variable for per study (e.g., this
occurred whenmore than one drug dose was administered
per sample or when floor/ceiling effects were suspected
for one outcome within a study but not for another). In
these cases, we relied on two approaches to analysis. First,
to satisfy the assumption of independence between effect
sizes, we excluded studies that included data on more than
one level of each moderator variable. In a second version
of the analyses, we used the shifting-unit method of
analysis (Cooper, 2010). The shifting-unit method allows
violation of the assumption of meta-analysis in which
a study can contribute an effect size to each level of the
moderator (e.g., high and low doses). The advantage of
the first approach is that the analysis assumptions remain
unviolated; the advantage of the second approach is that it
makes use of maximum possible data points. The findings
based on the two approaches were in agreement, so we
only report data based on the second one.
Publication Bias
Publication bias refers to the greater tendency of studies
with significant results to be published than nonsignificant
findings. Publication bias can therefore bias the results of
meta-analyses because the more significant findings typi-
cally have larger effect sizes than those remaining in file
drawers (Lipsey & Wilson, 2001). To minimize bias in
the current meta-analysis, we made efforts to locate and
retrieve unpublished data (see Search Strategies above).
In addition, we used three methods to assess the evidence
for publication bias and the stability of the effect size esti-
mates and to determine unbiased effect sizes: funnel plots,
fail-safe N, and trim and fill (Lipsey & Wilson, 2001). These
analyses were conducted without correcting effect sizes by
the factor J, as described earlier. Only data from published
reports were included in these analyses.
A funnel plot permits a qualitative test of publication bias
by showing the effect sizes of the analyzed studies plotted
against an estimate of those studies’ precision (the inverse
of standard error of the effect size in our graphs). Effect
size estimates from more accurate studies (toward the
top of the graph) should cluster closely around the true
effect size, whereas effect sizes from less accurate studies
should appear more broadly dispersed below. In the
absence of publication bias, the more broadly dispersed
effect size estimates should extend in a roughly symmetri-
cal arrangement to either side of the more accurate
estimates. A negative skew, where points in the lower
left quadrant appear to be missing, is consistent with the
operation of publication bias.
In cases of publication bias, the trim-and-fill procedure
calculates an unbiased estimate of the effect size. In this
procedure, the most extreme positive effects are removed
(“trimmed”) from analysis, and a mirror image of the
trimmed effect sizes with the opposite direction is then
imputed. Unbiased estimates of the overall effect size
and its variance are calculated, respectively, from the
trimmed and filled data.
The fail-safe N indicates the number of studies with
a zero effect size that, if added to the analysis, would
render the obtained mean effect size nonsignificant. The
value of fail-safe N is considered large (and publication
bias, an unlikely influence on the effect size estimate) if it
exceeds 5k + 10, where k is the number of meta-analyzed
studies (Rothstein, Sutton, & Borenstein, 2006).
Tests for Outliers
The presence of outlier effect sizes was assessed through
the sample-adjusted meta-analytic deviancy (SAMD) statis-
tic. For each study, the value of this statistic represents
the difference between this study’s effect size and the point
estimate of the effect size uninfluenced by this study, a dif-
ference weighed by the relevant variance terms (Huffcutt &
Arthur, 1995). An effect size was considered an outlier if it
met both of the following two criteria (Sockol, Epperson,
& Barber, 2011): First, in a scree plot of the distribution
of absolute SAMD values, it deviates markedly from the
slope (Huffcutt & Arthur, 1995). Second, it falls in the
top or bottom 2.5% of the SAMD distribution (which
approximates a t distribution). This conservative, two-
pronged method for outlier detection was chosen because
outliers could result from either error or true between-
study variation (Sockol et al., 2011).
Software
The data were analyzed primarily using Comprehensive
Meta-Analysis 2.0, with the exception of meta-regression
analyses, completed in R 3.0.0.
RESULTS
Overview of Results
We report meta-analyses for the effects of stimulants on
the four constructs of interest: inhibitory control, work-
ing memory, short-term episodic memory, and delayed
episodic memory. Two sets of results are presented, cor-
responding to the two different ways of measuring effect
sizes from within-subject designs described earlier. For
each cognitive construct, we first present meta-analyses
of within- and between-subject studies combined, measur-
ing the size of the drug effect relative to variability in the
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normal population. We then present the effect sizes esti-
mated in separate meta-analyses for within-subject and
matched-group studies using the formula for within-
subject effect sizes described earlier. For themain analyses,
we also report the results of moderator analyses and three
measures related to publication bias. In reporting our sec-
ondary analyses, we do not detail the results of moderator
and publication bias analyses, which, in all cases, were qual-
itatively similar to the results in our main analyses. Most ef-
fect sizes were small. Evidence of publication bias emerged
in two cognitive domains. Characteristics of all effect sizes
(outcomes, magnitude of effect, sample sizes, values of
moderator variables) are presented in Tables 2–5.
Stimulants’ Effects on Healthy Inhibitory Control
Twenty-five studies (including two unpublished) reported
sufficient data to calculate the size of stimulants’ effect
on inhibitory control. After examining the values of the
SAMD statistic, no value fell within the top or bottom
2.5% of the distribution or notably deviated from the rel-
atively flat line of the scree plot. Not all of these studies
were suitable for each analysis, that is, a study whose
effect size was derived from a repeated-measures t value
was excluded from analyses relative to normal variability;
and a between-subject study was excluded from analyses
relative to variability of change. Data for calculating effect
sizes relative to normal variability were available from
24 studies (see Table 2); effect size relative to variability
of gain scores was also estimated from 24 studies.
Stimulants’ mean effect on inhibitory control, when
measured relative to normative variability of perfor-
mance, was small but significantly different from zero:
Hedge’s g = 0.20, 95% CI [0.11, 0.30]. Effect size mea-
sured relative to the variability of gain scores was similarly
small and significantly different from zero: Hedge’s g =
0.19, 95% CI [0.11, 0.26]. No evidence for between-study
heterogeneity emerged: Q(23) = 7.82, p > .99, I2 = 0.00.
Moderator analyses indicated that none of the candidate
moderators impacted significantly the stimulant effects
on cognition (all ps > .20).
A funnel plot based only on the published studies (N=
22) showed no evidence for publication bias: The distri-
bution of studies was roughly symmetrical (Figure 2).
The trim-and-fill procedure led to the exclusion of no
study, and the adjusted effect size estimates remained
the same as reported above. However, the fail-safe N
method indicated that 39 studies (less than two studies
per each published report) with an effect size of zero
would nullify the obtained results. Taken together, the
lack of negative skew in the funnel plot and the robust-
ness of the effect size estimate to trim-and-fill adjustment
converge to suggest that the effect estimate obtained for
inhibitory control is most likely not affected by publica-
tion bias. In other words, there is no evidence to suspect
that the relatively modest number of studies needed to
nullify the result has remained in file drawers.
Stimulants’ Effects on Healthy Working Memory
Effect size data on stimulants’ effects on working memory
were available from 23 studies, three of which were un-
published. None of the effect sizes were outliers by our
criteria. Relevant statistics for calculating effect size rela-
tive to normal variability were available from 20 studies
(Table 3). Effect size relative to variability of gain scores
was calculated based on 23 studies with within-subject or
matched-group designs.
Our main analyses indicated a near-significant small
stimulant effect on working memory: Hedge’s g = 0.13,
95% CI [−0.02, 0.27]. When measured relative to var-
iability of the gain scores, the effect size was again esti-
mated to be small but, this time, reached significance:
g = 0.13, 95% CI [0.06, 0.20]. There was no significant
evidence for heterogeneity: Q(19) = 7.74, p = .99,
I2 = 0.00. Moderator analyses were performed, but no
evidence emerged for moderation by any of the exam-
ined variables.
The funnel plots, based on published studies only (Fig-
ure 3), showed slightly negative skew. The trim-and-fill
procedure trimmed 4 data points, reducing the above-
reported effect size to a nonsignificant trend of d = 0.06,
95% CI [−0.08, 0.20]. Because the gain score effect size
was significant, whereas the primary effect size was not,
here, we also report the trim-and-fill results from our sec-
ondary analyses, where the effect size was again reduced
to nonsignificant: d = 0.06, 95% CI [−0.03, 0.15], given a
negatively skewed funnel plot. Taken together, the trim-
and-fill correction and the skew of the funnel plot suggest
the presence of publication bias. Fail-safe N analyses were
obviated by the lack of significance in the obtained effect
size estimate.
Stimulants’ Effects on Healthy People’s Short-term
Episodic Memory
Fourteen effect sizes (one unpublished) were considered
for inclusion in the meta-analysis. Two SAMD values,
equaling −8.53 (Burns, House, Fensch, & Miller, 1967)
and 2.18 (Zeeuws, Deroost, & Soetens, 2010a), exceeded
the cutoff for exclusion and deviated markedly from the
relatively flat line on the scree plot of absolute SAMD
values. Therefore, these studies were excluded from fur-
ther analyses after confirming correct data entry.
On the basis of 12 studies (see Table 4), the mean ef-
fect of stimulants on short-term episodic memory, rela-
tive to normal variation of performance, was small but
significant: Hedge’s g = 0.20, 95% CI [0.01, 0.38]. This
was similar to the result observed when the effect size
was measured relative to variability of gain scores (12
studies): Hedge’s g = 0.22, 95% CI [0.09, 0.35]. No evi-
dence for heterogeneity emerged in our main analyses:
Q(11) = 4.44, p = .96, I2 = 0.00. Moderator analyses
indicated no significant influence of any of the examined
moderators (all ps > .64).
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Table 2. Stimulant Enhancement of Inhibitory Control: Effect Sizes and Study Characteristics
Study N
Target of
Recruitment
Age
(M)
Age
(Range)
%
Male
Education
( Years)
Mental Health
Assessment
Caffeine
Restriction Drug
Dose
(mg)
Dose
Coding Test Design
Floor or
Ceiling?
Other
Reason to
Publish? Hedge’s g
Acheson and
de Wit (2008)
28 Not specified 23.45 18–45 54.54 ≥12 SCID-I, SCL–90,
MAST
No Amp 20 High Stop signal task Within-subject Not
suspected
No 0.23
Agay, Yechiam,
Carmel, and
Levkovitz (2010)
25 Local community 32.65 21–50 46.15 M = 14.4 SCID-I, ASRS,
CAARS, WURS
No Mph 15 Low TOVA
(commissions)
Between-subject Possible No 0
Allman et al. (2010) 24 Not specified Not
reported
18–34 70.83 Not
reported
SCID-I No Amp 21 High Antisaccade task Within-subject Not
suspected
No 0.35
Barch and Carter
(2005)
22 Local community 36.6 Not
reported
55 M = 16 SCID, family
history of
psychosis
No Amp 17.5 Low Stroop Within-subject Not
suspected
No 0.23
Costa et al. (2013) 46 University and local
community
23.65 18–30 100 Not
reported
Clinician interview
(not specified)
Yes Mph 40 High Stop signal task,
go/no-go
Within-subject Not
suspected
No 0.07
de Bruijn, Hulstijn,
Verkes, Ruigt,
and Sabbe
(2004)
12 not specified 22.58 19–39 58.33 Not
reported
Not described No Amp 15 Low Flanker Within-subject Not
suspected
No 0.22
De Wit (2012) 207 Not specified Not
reported
18–35 52.43 ≥12 SCID-I, SCL-90 No Amp 5, 10, 20 Both Stop signal task Within-subject Not
suspected
No 0.21
De Wit et al. (2000) 20 University and local
community
25.9 21–35 70 ≥12 Semi-structured
psychiatric
screening, SCL-90
No Amp 10, 20 Both Stop signal task Within-subject Not
suspected
No 0.28
De Wit et al. (2002) 36 University and local
community
24 18–44 50 >12 Semistructured
psychiatric
interview,
SCL90, MAST
No Amp 10, 20 Both Stop signal task,
go/no-go
Within-subject Not
suspected
No 0.35
Engert, Joober,
Meaney,
Hellhammer,
and Pruessner
(2009)
43 University 22.2 Not
reported
100 Not
reported
Mini-SCID Yes Mph 20 Low WCST Between-subject Not
suspected
No 0.11
Farah (2012) 15 University and local
community
Not
reported
Not
reported
25 Not
reported
Self-reported
history of
diagnosis
No Amp 10 Low Flanker Within-subject Not
suspected
No 0.22
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Fillmore et al.
(2005)
22 Local community 21.5 18–30 45.45 M = 14.1
(range: 12–17)
Not described Yes Amp 7.5, 15 Low Stop signal task Within-subject Not
suspected
No 0.1
Hamidovic et al.
(2009)
93 Not specified 22.3 18–35 53.76 ≥12 Structured clinical
interview,
SCL-90, MAST
No Amp 5, 10, 20 Both Stop signal task Within-subject Not
suspected
Yes 0.2
Hester et al. (2012) 27 University 22 18–35 100 Not
reported
MINI, Kessler K10 Yes Mph 30 Low Go/no-go
(modified)
Within-subject Not
suspected
Yes 0.18
Ilieva et al. (2013) 43 University and local
community
24 21–30 50 Not
reported
Self-reported history
of diagnosis
No Amp 20 High Go/no-go,
flanker
Within-subject Not
suspected
No 0.05
Kelly et al. (2006) 20 University and local
community
21.7 Not
reported
50 M = 14.25 Not described No Amp 8, 15 Low Stop signal task Within-subject Not
suspected
No 0.09
Linssen, Vuurman,
Sambeth, and
Riedel (2012)
19 Local community 23.4 19–37 100 Not
reported
Not described No Mph 10, 20, 40 Both Stop signal task Within-subject Not
suspected
No 0.35
Mattay et al. (1996) 8 Not specified 25 22–32 50 Not
reported
Not described Yes Amp 17.5 Low WCST Within-subject Not
suspected
Yes 0.08
Moeller et al.
(2012)
15 Local community 38.9 Not
reported
93.33 M = 13.9 SCID-I, Addiction
Severity Index
No Mph 20 Low Stroop Within-subject Not
suspected
Yes 0.37
Nandam et al.
(2011)
24 University 23 18–35 100 Not
reported
M.I.N.I., Kessler K10 No Mph 30 Low Stop signal task Within-subject Not
suspected
Yes 0.58
Pauls et al. (2012) 16 University 23.6 19–30 100 Not
reported
ASRS; assessment
of other
psychopathology
not described
Yes Mph 40 High Stop signal task Within-subject Not
suspected
Yes 0.32
Servan-Schreiber,
Carter, Bruno,
and Cohen
(1998)
8 University Not
reported
24–39 50 Not
reported
SCID-I No Amp 17.5 Low Flanker Within-subject Not
suspected
No 0.72
Sofuoglu, Waters,
Mooney, and
Kosten (2008)
10 Local community 27.7 Not
reported
58.33 Not
reported
Psychiatric
examination
(not specified)
No Amp 20 High Go/no-go Within-subject Possible Yes −0.36
Theunissen, Elvira,
van den Bergh,
and Ramaekers
(2009)
16 Local community 21.8 19–29 31.25 Not
reported
Not described Yes Mph 20 Low Stop signal task Within-subject Not
suspected
Yes −0.01
Overall effect size 0.20
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Table 3. Stimulant Enhancement of Working Memory: Effect Sizes and Study Characteristics
Study N
Target of
Recruitment
Age
(M)
Age
(Range)
%
Male
Education
( Years)
Mental
Health
Assessment
Caffeine
Restriction Drug
Dose
(mg)
Dose
Coding Test
Stimulus
Modality
Type of WM
Processing Design
Floor or
Ceiling?
Other
Reason to
Publish?
Hedge’s
g
Agay et al.
(2010)
26 Local
community
32.65 21–50 56.25 M = 14.4 SCID-I, ASRS,
CAARS, WURS
No Mph 15 Low Digit span Verbal Maintenance only,
maintenance +
manipulation
Between-
subject
Not
suspected
Yes 0.22
Agay (2012) 19 Local
community
Not
reported
20–40 Not
reported
Not
reported
SCID-I No Mph 20 Low Digit Span,
CANTAB
Spatial WM
Spatial,
verbal
Maintenance only,
maintenance
+
manipulation
Within-
subject
Not
suspected
Yes 0.23
Barch and
Carter
(2005)
22 Local
community
36.6 Not
reported
55 M = 16 SCID, family
history of
psychosis
No Amp 17.5 Low Spatial working
memory
(8-sec delay,
single and
dual tasks)
Spatial Maintenance only,
maintenance
+
manipulation
Within-
subject
Not
suspected
Yes 0.10
Dorflinger
(2005)
20 Not
specified
27.9 24–34 Not
reported
M = 16.5
(range: 12–22)
Not described No Mph 14, 28 Low 2-back, 3-Back Verbal Maintenance +
manipulation
Within-
subject
Not
suspected
Yes 0.15
Farah (2012) 16 University
and local
community
Not
reported
Not
reported
25 Not
reported
Self-reported
history of
diagnosis
No Amp 10 Low Digit Span,
2-back
Visual,
verbal
Maintenance only,
maintenance
+
manipulation
Within-
subject
Not
suspected
No −0.10
Fillmore et al.
(2005)
22 Local
community
21.5 18–30 45.45 M = 14.1
(range: 12–17)
Not described Yes Amp 7.5, 15 Low Rapid Inf.
processing
Verbal Maintenance +
manipulation
Within-
subject
Not
suspected
No 0.25
Ilieva et al.
(2013)
43 University
and local
community
24 21–30 50 Not
reported
Self-reported
history of
diagnosis
No Amp 20 High Digit Span,
2-back
Visual,
verbal
Maintenance only,
maintenance
+
manipulation
Within-
subject
Not
suspected
No 0.01
Kelly et al.
(2006)
20 University
and local
community
21.7 Not
reported
50 M = 14.25 Not described No Amp 7.5, 15 Low Rapid Inf.
Processing
Verbal Maintenance +
manipulation
Within-
subject
Not
suspected
No 0.38
Linssen et al.
(2012)
19 Local
community
23.4 19–37 100 Not
reported
Not described Yes Mph 10, 20, 40 Low,
high
Spatial working
memory
Spatial Maintenance +
manipulation
Within-
subject
Not
suspected
No 0.41
Marquand et al.
(2011)
15 University
and local
community
Not
reported
20–39 100 Not
reported
Interview (not
specified)
Yes Mph 30 Low Spatial working
memory
(unrewarded
condition)
Spatial Maintenance only Within-
subject
Not
suspected
Yes −0.11
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Mattay et al.
(2000)
10 Not
specified
Not
reported
Not
reported
80 Not
reported
Not described Yes Amp 17.5 Low 2-back, 3-back Verbal Maintenance +
manipulation
Within-
subject
Not
suspected
Yes −0.04
Mattay et al.
(2003)
26 Not
specified
Not
reported
<45 40.74 Not
reported
Not described No Amp 17.5 Low 2-back, 3-back Verbal Maintenance +
manipulation
Within-
subject
Not
suspected
Yes −0.23
Mehta et al.
(2000)
10 Not
specified
34.8 Not
reported
100 Not
reported
Not described No Mph 40 High CANTAB Spatial
Working
Memory
Spatial Maintenance +
manipulation
Within-
subject
Not
suspected
Yes 0.27
Mintzer and
Griffiths
(2003)
20 Not
specified
30 19–52 70 12–16,
M = 14
Not described No Amp 20 High Digit Recall,
2-back
Verbal Maintenance only,
maintenance
+
manipulation
Within-
subject
Possible for
onemeasure
Yes 0.25
Mintzer and
Griffiths
(2007)
18 Not
specified
23 18–39 61.11 12–21,
M = 15
Not described No Amp 20, 30 High 2-back, 3-back,
modified
Sternberg
Verbal Maintenance +
manipulation
Within-
subject
Not
suspected
Yes 0.15
Oken, Kishiyama,
and Salinsky
(1995)
23 Not
specified
25 21–39 47.83 Not
reported
Not described Yes Mph 14 Low Digit Span Verbal Maintenance only,
maintenance
+
manipulation
Within-
subject
Not
suspected
Yes −0.14
Ramasubbu,
Singh, Zhu,
and Dunn
(2012)
13 University 28 Not
reported
38.46 Not
reported
Not described Yes Mph 20 Low 2-back Verbal Maintenance +
manipulation
Within-
subject
Not
suspected
Yes 0.62
Schmedtje,
Oman,
Letz, and
Baker (1988)
8 Not
specified
Not
reported
Not
reported
Not
reported
Not
reported
Not described No Amp 5 Low Digit Span,
pattern
memory
Visual,
verbal
Maintenance only,
maintenance
+
manipulation
Within-
subject
Not
suspected
Yes 0.30
Silber, Croft,
Papafotiou,
and Stough
(2006)
20 Local
community
25.4 21–32 50 ≥11 Clinician
screening
(not specified)
Yes Amp 5 Low Digit Span Verbal Maintenance only,
maintenance
+
manipulation
Within-
subject
Not
suspected
Yes 0.18
Studer et al.
(2010)
11 Not
specified
29.7 Not
reported
45.45 Not
reported
Not described No Mph 20 Low Visual working
memory
Visual Maintenance +
manipulation
Within-
subject
Possible for
onemeasure
Yes 0.10
Overall effect size 0.13
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Table 4. Stimulant Enhancement of Short-term Episodic Memory: Effect Sizes and Study Characteristics
Study N
Target of
Recruitment
Age
(M)
Age
(Range)
%
Male
Education
(Years)
Mental
Health
Assessment
Caffeine
Restriction Drug
Dose
(mg)
Dose
Coding Test
Retention
Interval Design
Floor or
Ceiling?
Other
Reason to
Publish?
Hedge’s
g
Farah (2012) 16 University
and local
community
Not
reported
Not
reported
25 Not
reported
Self-
reported
history of
diagnosis
No Amp 10 Low Word recall,
word
recognition,
face recognition
30 min Within-
subject
Not
suspected
No 0.07
Fleming,
Bigelow,
Weinberger,
and Goldberg
(1995)
17 Local
community
27.5 Not
reported
52.94 M = 15.8 SCID-I and II No Amp 20 High Paired associates,
Rey Verbal
Learning Test
Immediate Within-
subject
Possible
for one
measure
No 0.16
Linssen et al.
(2012)
19 Local
community
23.4 19–37 100 Not
reported
Not
described
No Mph 10, 20, 40 Low,
high
Word recall,
word recognition
Immediate;
30 min
Within-
subject
Possible
for one
measure
No 0.20
Soetens et al.
(1995),
Study 1
18 Not
specified
Not
reported
19–25 100 Not
reported
Not
described
No Amp 10 Low Word recall Immediate Within-
subject
Not
suspected
No 0.23
Soetens et al.
(1995),
Study 2
14 Not
specified
Not
reported
19–25 100 Not
reported
Not
described
No Amp 10 Low Word recall Immediate Within-
subject
Not
suspected
No 0.39
Soetens et al.
(1995), Study 4
12 Not
specified
Not
reported
19–25 100 Not
reported
Not
described
No Amp 10 Low Word recognition Immediate Within-
subject
Not
suspected
No 0.29
Soetens et al.
(1995),
Study 5
12 Not
specified
Not
reported
19–25 100 Not
reported
Not
described
No Amp 10 Low Word recognition Immediate Within-
subject
Not
suspected
No 0.31
Unrug,
Coenen, and
van Luijtelaar
(1997)
12 University 24 19–27 50 Not
reported
Not
described
Yes Mph 20 Low Word recall 20 min Within-
subject
Possible
for one
measure
Yes 0.32
Willett (1962) 37 Not
specified
Not
reported
Not
reported
0 Not
reported
Not
described
No Amp 10 Low Learning of
nonword lists
Immediate Between-
subject
Not
suspected
No 0.22
Zeeuws, Deroost,
and Soetens
(2010b),
Study 1
24 University 21.1 18–25 100 Not
reported
Not
described
No Amp 10 Low Word recognition Immediate Within-
subject
Not
suspected
No −0.17
Zeeuws et al.
(2010b),
Study 2
16 University 21.4 18–25 100 Not
reported
Not
described
No Amp 10 Low Word recognition Immediate Within-
subject
Not
suspected
No −0.13
Zeeuws and
Soetens
(2007)
36 University Not
reported
18–25 100 Not
reported
Not
described
No Amp 10 Low Word recognition Immediate;
30 min
Within-
subject
Not
suspected
No 0.45
Overall effect size 0.20
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Table 5. Stimulant Enhancement of Long-term Episodic Memory: Effect Sizes and Study Characteristics
Study N
Target of
Recruitment
Age
(M)
Age
(Range)
%
Male
Education
(Years)
Mental
Health
Assessment
Caffeine
Restriction Drug
Dose
(mg)
Dose
Coding Test
Retention
Interval Design
Floor or
Ceiling?
Other
Reason to
Publish?
Hedge’s
g
Brignell,
Rosenthal,
and Curran
(2007)
36 Not
specified
22.8 18–35 Not
reported
Not
reported
Not
described
No Mph 40 High Recognition
memory
for narratives
1 hr,
1 day
Between-
subject
Not
suspected
Yes 0.52
Ilieva et al.
(2013)
18 University
and local
community
24 21–30 50 Not
reported
Self-
reported
history of
diagnosis
No Amp 20 High Word recall and
recognition,
face recognition
2 hr Within-
subject
Not
suspected
No 0.01
Mintzer and
Griffiths
(2003)
16 Not
specified
30 19–52 70 12–16,
M = 14
Not
described
No Amp 20 High Word recall and
recognition
2 hr Within-
subject
Not
suspected
Yes 0.24
Mintzer and
Griffiths
(2007)
20 Not
specified
23 18–39 61.11 12–21,
M = 15
Not
described
No Amp 20,
30
High Word recall and
recognition
2 hr Within-
subject
Not
suspected
Yes 0.33
Soetens et al.
(1995),
Study 1
44 Not
specified
Not
reported
19–25 100 Not
reported
Not
described
No Amp 10 Low Word recall 1 day Within-
subject
Not
suspected
No 0.71
Soetens et al.
(1995),
Study 2
18 Not
specified
Not
reported
19–25 100 Not
reported
Not
described
No Amp 10 Low Word recall 1 hr,
1 day
Within-
subject
Not
suspected
No 0.58
Soetens et al.
(1995),
Study 4
14 Not
specified
Not
reported
19–25 100 Not
reported
Not
described
No Amp 10 Low Word recall 1 day,
2 days,
3 days
Within-
subject
Not
suspected
No 0.58
Soetens et al.
(1995),
Study 5
12 Not
specified
Not
reported
19–25 100 Not
reported
Not
described
No Amp 10 Low Word recognition 1 day,
1 week
Within-
subject
Not
suspected
No 0.74
Zeeuws et al.
(2010b),
Study 1
12 University 21.1 18–25 100 Not
reported
Not
described
No Amp 10 Low Word recognition 1 hr,
1 day,
1 week
Within-
subject
Not
suspected
No 0.69
Zeeuws et al.
(2010b),
Study 2
24 University 21.4 18–25 100 Not
reported
Not
described
No Amp 10 Low Word recognition 1 hr,
1 day,
1 week
Within-
subject
Not
suspected
No 0.18
Zeeuws and
Soetens
(2007)
16 University Not
reported
18–25 100 Not
reported
Not
described
No Amp 10 Low Word recognition 1 hr,
1 day
Within-
subject
Not
suspected
No 0.80
Overall effect
size
0.45
Ilieva
,
H
ook,
a
n
d
Fa
ra
h
15
A funnel plot, based on the 11 published studies,
showed slightly negative asymmetry (Figure 4); yet,
inconsistent with publication bias, the largest study had
the largest effect. The trim-and-fill procedure trimmed
three studies, reducing the effect size estimate to a non-
significant d = 0.12, 95% CI [−0.06, 0.29]. The fail-safe N
procedure showed that a mere two studies with an effect
size of zero would be needed to nullify the obtained
effect, casting doubt on this effect’s robustness.
Stimulant Effects on Healthy People’s Delayed
Episodic Memory
Twelve effect sizes describing stimulants’ effects on
delayed episodic memory were reported. One outlier
was excluded, given an SAMD value of 3.35 (Zeeuws
et al., 2010a), which fell in the top 2.5% of the distribution
of SAMD scores.
On the basis of the remaining 11 effect sizes, estimated
relative to normal variability (see Table 5), stimulants’
mean effect on delayed episodic memory was signifi-
cantly different from zero and medium in size: g = .45,
95% CI [0.27, 0.63]. Similarly, analyses focusing on the
mean gain, relative to the sample’s variability of change,
showed a medium-sized effect: Hedge’s g = 0.44, 95% CI
[0.26, 0.62]. There was no evidence for significant between-
study heterogeneity: I2 = 0.00, Q(10) = 9.67, p = .47.
We found a small but significant moderating effect of
gender, Q(1) = 7.44, p < .01, β = 0.01, with larger drug
effects for larger proportions of men in samples. In addi-
tion, there was a significant moderating effect of dose,
Q(1) = 5.49, p = .02, indicating a larger effect for the
smaller dose, Hedge’s g = 0.64, 95% CI [0.40, 0.88], than
the larger dose, Hedge’s g = 0.20, 95% CI [−0.08, 0.48].
Note that these moderation effects are confounded with
each other and with research group: All studies that used
low doses of stimulants came from the same research
group, tested only male participants, and tended to in-
clude memory tests at longer retention intervals (up to
1 week), whereas among tests of the high drug dose, the
percentage of men in the sample ranged between 48%
and 70% and retention intervals, with one exception, were
2 hr. No other factors were found to significantly moderate
stimulants’ effects (all ps > .52).
The funnel plot of these studies was negatively
skewed, suggesting publication bias (Figure 5). The
Figure 2. Funnel plot of publication bias: inhibitory control.
Figure 3. Funnel plot of publication bias: working memory. Darkened
data points represent studies “filled” by trim and fill.
Figure 4. Funnel plot of publication bias: short-term episodic memory.
Darkened data points represent studies “filled” by trim and fill.
Figure 5. Funnel plot of publication bias: long-term episodic memory.
Darkened data points represent studies “filled” by trim and fill.
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trim-and-fill method trimmed five studies, reducing the
estimated effect size to d = 0.26, 95% CI [0.04, 0.47]. Ac-
cording to the fail-safe N procedure, 59 studies were
needed to nullify the significance level of the result.
The negative skew of the funnel plot, combined with
the trim-and-fill correction, suggests the presence of pub-
lication bias and indicates that the true effect size may be
small. It is important to note, though, that inferences
from the funnel plot are qualified by the presence of sig-
nificant moderation (see Lau, Ioannidis, Terrin, Schmid,
& Olkin, 2006). In particular, the studies with the six larg-
est effect sizes came from the same laboratory and tested
the effect of a low stimulant dose on male-only samples,
in part, over relatively longer retention intervals. Four of
the five remaining studies with smaller effect sizes came
from other research groups and examined the effects of a
high stimulant dose on a mixed-gender sample over rel-
atively shorter delays. Thus, the funnel plot might reflect
true publication bias or might be driven by between-
study differences. If the latter is the case, the trim-and-
fill-adjusted effect size may be underestimating the true
effect size (e.g., Peters, Sutton, Jones, Abrams, & Rushton,
2007). Unfortunately, the proposed methods of uncon-
founding publication bias and moderating factors (e.g.,
conducting funnel plot analyses within a subgroup of
studies) are applicable only to large meta-analyses (see
Peters et al., 2010).
DISCUSSION
Summary and Interpretation of Results
Earlier research has failed to distinguish whether stimu-
lants’ effects are small or whether they are nonexistent
(Ilieva et al., 2013; Smith & Farah, 2011). The present find-
ings supported generally small effects of amphetamine and
methylphenidate on executive function and memory. Spe-
cifically, in a set of experiments limited to high-quality
designs, we found significant enhancement of several cog-
nitive abilities. We found a small but significant degree of
enhancement of inhibitory control and short-term episodic
memory. Effects on working memory were small and sig-
nificant in one of our two analyses. Delayed episodic
memory was unique in showing a medium-sized effect.
However, both working memory and delayed episodic
memory findingswere qualified by possible publication bias.
Theoretically, the relatively more pronounced effects
of delayed episodic memory, in comparison with short-
term episodic memory, suggest that stimulants may be
affecting most potently memory consolidation in compari-
son with encoding or retrieval. This conclusion is consistent
with previous proposals (e.g., Soetens, Hueting, Casaer, &
D’Hooge, 1995; see also McGaugh & Roozendaal, 2009)
but, again, qualified by the possibility of publication bias.
Several potentially important moderators were tested
because of their scientific relevance for understanding the
effects of stimulants on cognition and their practical rele-
vance in determining whether stimulants might be more
effective cognitive enhancers under some circumstances
than others. Moderator analyses yielded only a few signifi-
cant findings. Stimulant effects on delayed episodic memory
were moderated by gender, with larger effects for samples
with more men, and by dosage, with larger effects for
smaller doses. Unfortunately, these two moderators were
confounded in the studies analyzed and also confounded
with research laboratory and retention interval, so we cannot
draw firm conclusions about the effects of gender or dose.
Where no effects of moderators were found, this may
be because of uncertainty or imprecision in moderator
coding, for instance, the dichotomization of drug dose
or the possibility of nonlinear relationships between
drug effect and dose. Finally, partly for the sake of limit-
ing the number of comparisons and partly because of
limited availability of relevant information, we examined
only a subset of all relevant moderators. For instance,
we did not explore the moderating role of participant
age, level of education, waiting time between drug ad-
ministration and testing, length of testing session, or
time of day. Moderators of great interest, which might
be expected to affect results based on previous studies
but which could not be assessed because of insufficient
available data, include individuals’ baseline cognitive
ability and individuals’ variants of dopamine-related
genes such as COMT and DRD2 (see Hamidovic et al.,
2009; Mattay et al., 2003; but see also Wardle, Hart,
Palmer, & de Wit, 2013, for null results). Consistent with
the nonmonotonic relation between dopamine activity
and performance, there is evidence that stimulants can
impair performance in normal individuals who are espe-
cially high performing (Farah, Haimm, Sankoorikal, &
Chatterjee, 2009; De Wit et al., 2002; De Wit, Crean, &
Richards, 2000; Mattay et al., 2000). It remains possible
that some individuals who would not qualify for a diagnosis
of ADHD could nevertheless benefit from stimulants to a
greater degree than indicated by the present results and
that some individuals could be impaired.
Could the effects documented here be driven by undiag-
nosed psychopathology in some participants? One might
expect participants with ADHD or depression to perform
better on stimulants and participants with anxiety disorders
or bipolar disorder to be impaired by these drugs. Unfortu-
nately, few publications included comprehensive, detailed
description of procedure through which psychopathology
was screened out, making it difficult to assess the quality
of assessment. Nevertheless, all reports explicitly described
their samples as “healthy” or “nonclinical.” Thus, it is
possible but unlikely that unrecognized mental illness is
responsible for the pattern of obtained findings.
Neuroethical Implications
What do the results reported here imply for neuroethical
issues surrounding the use of stimulants for enhancement?
Should we be concerned about the fairness of students
and workers competing with the help of stimulant drugs?
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Is there a genuine benefit to be weighed against the risks
of using these prescription drugs for enhancement? The
overall small effects of stimulants on healthy people’s
inhibitory control and working and episodic memory
might be taken to mean that these drugs would not deliver
a practically significant performance advantage. If so, one
might argue that neuroethical discussions are therefore
moot at best (and encouraging of a false belief in the drugs’
efficacy at worst, e.g., Hall & Lucke, 2010).
The present findings should temper these and other
more skeptical assessments of stimulant medications for
cognitive enhancement of healthy, cognitively normal indi-
viduals. Although the reported effects are smaller than
these of some other cognitive enhancement techniques
(e.g., mindfulness meditation, for which near-medium
effects on inhibitory control have been documented; see
Sedlmeier et al., 2012, for a meta-analysis), the present
findings show stimulant benefits comparable with the
effects of other commonly used enhancement tools (e.g.,
physical exercise, the cognitive effects of which have been
found to be similarly small; see Chang, Labban, Gapin,
& Etnier, 2012, for a meta-analysis). Furthermore, small
effects can make a difference in academic and professional
outcomes. Even on a single occasion, a small effect might
make the difference between good and very good perfor-
mance or between passing a school entrance or licensing
examination or failing. It is also possible that these drugs
may give a larger boost to cognitive functions not examined
here (e.g., sustained attention, processing speed); to people
not specifically studied in this meta-analysis (e.g., healthy
participants with low cognitive performance or specific
genotypes); or to performance under conditions not tested
here, for example, fatigue, sleep deprivation, distraction, or
repeated stimulant use (e.g., Breitenstein et al., 2006). It is
also possible that stimulants enhance cognitive performance
in real-world contexts at least in part through effects on
users’ affective states. They have been found to alter users’
emotions about, and interest in, tasks otherwise seen as bor-
ing and unrewarding (Ilieva & Farah, 2013; Vrecko, 2013).
The results of this meta-analysis cannot address the
important issues of individual differences in stimulant
effects or the role of motivational enhancement in
helping perform academic or occupational tasks. How-
ever, they do confirm the reality of cognitive enhancing
effects for normal healthy adults in general, while also
indicating that these effects are modest in size.
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Notes
1. Correlations were obtained from Ilieva, Boland, and Farah
(2013; Flanker, Go/No-Go, n-back, Digit Span Backward and
Forward, delayed memory for words and faces; 46 participants);
Mintzer and Griffiths (2007; n-back, Sternberg memory task,
delayed memory for words; 18 participants); and Hamidovic,
Dlugos, Skol, Palmer, and de Wit (2009), combined with a set
of unpublished data from Dr. Harriet de Wit’s laboratory (Stop
Signal task, 299 participants). When correlations for a given task
(e.g., n-back) were available from more than one data set, we
estimated a composite through meta-analyzing the available
correlations based on a random effects model. In the case of
tasks for which data on observed correlations were lacking,
we imputed an estimate of the correlation for the correspond-
ing cognitive construct obtained through meta-analyzing the
available observed correlations for tasks within that construct
based a random effects model.
2. To estimate the potential for error in case of inaccurate im-
puted correlations, we repeated our main analyses three times
after imputing uniform correlation values of .2, .5, and .8 across
all effect sizes. This led to minimal changes in the reported
patterns of findings (largest change in effect size was g = 0.02).
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